View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
May 13, 2020

Glenmark begins Phase III trials of favipiravir for Covid-19 in India

India-based Glenmark Pharmaceuticals has started Phase III clinical trials of anti-flu drug favipiravir as a potential treatment for patients suffering from Covid-19 in the country.

More than ten government and private hospitals in India are being recruited for the trial.

 

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena